



Hollis-Eden Pharmaceuticals, Inc.  
4445 Eastgate Mall, Suite 400  
San Diego, CA 92121  
Telephone: 858 587 9333  
Fax: 858 558 6470

JKW

1615



**HOLLISEDEN**  
PHARMACEUTICALS  
*Serving Humanity*

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CERTIFICATE OF MAILING BY "FIRST-CLASS MAIL"**

**Attorney Docket No. :** 202.8  
**Serial No. :** 10/087,929  
**Applicant(s) :** Clarence N. Ahlem, et al.  
**For :** Blood Cell Deficiency Treatment Method  
**Attorney :** Daryl D. Muenchau, Reg. No. 36,616  
**Date of Deposit :** August 13, 2004

I hereby certify that the accompanying

Transmittal (in duplicate); Information Disclosure Statement (Form PTO-1449 (34 references); and Return Postage Prepaid Postcard

are being deposited with the United States Postal Service "First-Class Mail" service on the date indicated above and are addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Candace Pinelli  
Candace Pinelli



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Clarence N. Ahlem, et al.  
Application No. : 10/087,929  
Filed : March 1, 2002  
Title : Blood Cell Deficiency Treatment Method  
Examiner : James M. Spear  
TC/A.U. : 1615  
  
Docket No. : 202.8  
Customer No. : 26551  
Confirmation No. : 7989

---

**SUPPLEMENTAL INFORMATION**  
**DISCLOSURE STATEMENT TRANSMITTAL**

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 (in duplicate) listing 34 references. A copy of foreign patent documents and other documents are enclosed. This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b). Please charge any fees due or credit any overpayments to **Deposit Account No. 501536**. A duplicate copy of this sheet is enclosed.

Please direct all correspondence to **Customer No. 26,551**.

Respectfully submitted,

HOLLIS-EDEN PHARMACEUTICALS, INC.

Dated:

Aug. 13, 2004

By:

Daryl D. Muenchau

Daryl D. Muenchau, Reg. No. 36,616  
Hollis-Eden Pharmaceuticals, Inc.  
4435 Eastgate Mall, Suite 400  
San Diego, California, 92121  
Telephone: (858) 587-9333  
**Customer No. 26,551**



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Clarence N. Ahlem, et al.  
Application No. : 10/087,929  
Filed : March 1, 2002  
Title : Blood Cell Deficiency Treatment Method  
Examiner : James M. Spear  
TC/A.U. : 1615  
  
Docket No. : 202.8  
Customer No. : 26551  
Confirmation No. : 7989

---

**SUPPLEMENTAL INFORMATION**  
**DISCLOSURE STATEMENT TRANSMITTAL**

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 (in duplicate) listing 34 references. A copy of foreign patent documents and other documents are enclosed. This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b). Please charge any fees due or credit any overpayments to **Deposit Account No. 501536**. A duplicate copy of this sheet is enclosed.

Please direct all correspondence to **Customer No. 26,551**.

Respectfully submitted,


HOLLIS-EDEN PHARMACEUTICALS, INC.

Dated: Aug. 13, 2004

By: Daryl D. Muenchau  
Daryl D. Muenchau, Reg. No. 36,616  
Hollis-Eden Pharmaceuticals, Inc.  
4435 Eastgate Mall, Suite 400  
San Diego, California, 92121  
Telephone: (858) 587-9333  
**Customer No. 26,551**

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
202.8APPLICATION NO.  
10/087,929SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

USE SEVERAL SHEETS IF NECESSARY

APPLICANT  
Ahlem, et al.FILING DATE  
3/1/02GROUP  
1615

## U.S. PATENT DOCUMENTS

| EXAMINER<br>INITIAL | DOCUMENT NUMBER | ISSUE<br>DATE | NAME | CLASS | SUBCLASS | FILING DATE<br>IF APPROPRIATE |
|---------------------|-----------------|---------------|------|-------|----------|-------------------------------|
|                     |                 |               |      |       |          |                               |

## U.S. PATENT APPLICATION PUBLICATIONS

| EXAMINER<br>INITIAL | PUBLICATION NUMBER | NAME          | CLASS | SUBCLASS | FILING DATE<br>IF APPROPRIATE |
|---------------------|--------------------|---------------|-------|----------|-------------------------------|
| .                   | 2002/0019376 A1    | Savage et al. |       |          |                               |
|                     | 2004/0097406 A1    | Ahlem et al.  |       |          |                               |
| .                   | 2003/0113284 A1    | Dalko et al.  |       |          |                               |
|                     | 2002/0091278 A1    | Savage et al. |       |          |                               |
|                     | 2003/0060425 A1    | Ahlem et al.  |       |          |                               |
|                     | 2004/0116359 A1    | Ahlem et al.  |       |          |                               |
|                     | 2004/0060425 A1    | Ahlem et al.  |       |          |                               |
|                     | 2002/0187973 A1    | Labrie        |       |          |                               |
|                     | 2004/0043973 A1    | Ahlem et al.  |       |          |                               |
|                     | 2004/0082556 A1    | Labrie et al. |       |          |                               |
|                     | 2003/0083231 A1    | Ahlem et al.  |       |          |                               |

## FOREIGN PATENT DOCUMENTS

| EXAMINER<br>INITIAL | DOCUMENT NUMBER | PUB.<br>DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION |    |
|---------------------|-----------------|--------------|---------|-------|----------|-------------|----|
|                     |                 |              |         |       |          | YES         | NO |
|                     | EP 0 576 915 B1 | 01/05/94     | Europe  |       |          |             |    |
|                     | WO 99/08684     | 08/17/98     | PCT     |       |          |             |    |
|                     | WO 97/41867     | 11/13/97     | PCT     |       |          |             |    |
|                     | EP 0 576 914 A2 | 01/05/94     | Europe  |       |          |             |    |
|                     |                 |              |         |       |          |             |    |
|                     |                 |              |         |       |          |             |    |
|                     |                 |              |         |       |          |             |    |

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

|   |  |                            |                               |
|---|--|----------------------------|-------------------------------|
| FORM PTO-1449   | U.S. DEPARTMENT OF COMMERCE<br>PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO.<br>202.8  | APPLICATION NO.<br>10/087,929 |
| SUPPLEMENTAL INFORMATION DISCLOSURE<br>STATEMENT BY APPLICANT |  | APPLICANT<br>Ahlem, et al. |                               |
|   |  | FILING DATE<br>3/1/02      | GROUP<br>1615                 |

USE SEVERAL SHEETS IF NECESSARY



| EXAMINER<br>INITIAL | OTHER DOCUMENTS INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.   |
|---------------------|--|
|                     | Wheeler, O., et al, "Steroid derivatives of cysteamine and cysteine", <i>Canadian J of Chem</i> , Vol 47, pp 160-62 (1969)   |
|                     | Kondziolka, D., et al, "Beneficial effects of the radioprotectant 21-aminosteroid U-74389G in a radiosurgery rat malignant glioma model", <i>Int. J. Rad. Onc. Biol. Phys.</i> , Vol 44 (1), pp. 179-84 (1999)   |
|                     | Evens, R., et al, "Androgens and erythropoiesis", <i>J. Clin. Pharm.</i> , pp. 94-101 (1974)   |
|                     | Sigg, H., et al, "Helvetica Chimica ACTA", Vol. 39 (6), pp. 1507 - 1525 (1956)   |
|                     | Mulder, et al., "Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic human immunodeficiency virus-infected men", <i>J. of Infectious Diseases</i> , 165, pp. 413-18 (1992)   |
|                     | Clerici, et al., "A possible role for the cortisol/anticortisol imbalance in the progression of human immunodeficiency virus", <i>Psychoneuroendocrinology</i> 22 (Suppl 1), pp S27-S31 (1997)   |
|                     | Rasmussen, K., et al, "Effects of dehydroepiandrosterone in immunosuppressed rats infected with cryptosporidium parvum", <i>J. Parasitol</i> , Vol. 79 (3), pp. 364-70 (1993)  |
|                     | Loria, et al., "Androstenediol regulates systemic resistance against lethal infections in mice", <i>archives of Virology</i> , 127, pp. 105-15 (1992)  |
|                     | Gidari, A., et al, "Cyproterone-mediated stimulation of $\delta$ -aminolevulinic acid synthetase in chick embryo liver cells", <i>Endocrinology</i> , 99, pp. 130-36 (1976)  |
|                     | Morrow, D., et al, "The synthesis of 17 $\beta$ -amino-17-isoprogesterone", <i>J Org Chem</i> , pp 579-87 (1965)   |
|                     | Goldman, A., et al, "Inhibitors of human placental C <sub>19</sub> and C <sub>21</sub> 3 $\beta$ -hydroxysteroid dehydrogenases", <i>Biochimica et Biophysica Acta</i> , 315, pp. 233-49 (1973)  |
|                     | Padgett, et al., "In vitro potentiation of lymphocyte activation by dehydroepiandrosterone, androstenediol, and androstenediol", <i>J. of Immunology</i> , 153, pp. 1544-52 (1994)   |
|                     | Moog, et al., "Oxysterols, but not cholesterol, inhibit human immunodeficiency virus replication in vitro", <i>Antiviral Chememistry &amp; Chemotherapy</i> , pp. 9, pp. 491-96 (1998)   |
|                     | Xia, P, et al, "Anti-AIDS agents. Part 36: 17-carboxylated steroids as potential anti-HIV agents", <i>Bioorganic &amp; Medicinal Chem</i> , 7, pp. 1907-11 (1999)  |
|                     | Daigle, J., et al., "Androstenediol antagonizes herpes simplex virus type 1-induced encephalitis through the augmentation of type 1 IFN production", <i>The J of Immunology</i> , pp. 3060 - 3066 (1998)   |
|                     | Lafaye, P. et al., "The 7 $\alpha$ -hydroxysteroids produced in human tonsils enhance the immune response to tetanus toxoid and Bordetella pertussis antigens", <i>Biochimica et Biophysica Acta</i> , 1472, pp. 222 - 31 (1999)                         |
|                     | Faredin, I., et al., "Transformation in vitro of [4- <sup>14</sup> C]-dehydroepiandrosterone into 7-oxygenated derivatives by normal human male and female skin tissue", <i>The J of Investigative Dermatology</i> , Vol. 52, No. 4, pp. 357 - 61 (1969) |
|                     | Davis, A., et al, "Stereocontrolled synthesis of cholic acid derivatives with N-protected 7 $\beta$ -and/or 12 $\beta$ -amino substituents", <i>Tetrahedron Letters</i> , Vol 33, No. 35, pp. 5111-12 (1992)   |
|                     | Davis, M., et al, "Steroid amines. Part IV. 3,17-diaminoandrostane derivatives", <i>J Chem. Soc</i> , 11, pp. 1045 - 52 (1967)   |

|  |                 |
|--|-----------------|
| EXAMINER   | DATE CONSIDERED |
| *EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT. |                 |